ASHLEIGH REIMANN: Open Payments
NPI 1154738771 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,377 in 68 payments from 20 companies in 2025. Trend: 2023 $1,497 · 2024 $1,485 · 2025 $1,377
Food & beverage: $1,377
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $225 |
| GlaxoSmithKline, LLC. | 9 | $199 |
| Mallinckrodt Hospital Products Inc. | 8 | $181 |
| Merck Sharp & Dohme LLC | 7 | $139 |
| AstraZeneca Pharmaceuticals LP | 5 | $101 |
| Vifor Pharma, Inc. | 3 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $66 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $46 |
Products named: TEZSPIRE, ACTHAR, ZERBAXA, TRELEGY ELLIPTA, DUPIXENT, Zemaira, OFEV, NUCALA.
Industry payments across AL — which companies pay providers there.
